British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

Thorax

Volumn 72, Issue , 2017, Pages ii1-ii64

  Haworth, Charles S ^a   Banks, John ^b   Capstick, Toby ^c   Fisher, Andrew J ^d   Gorsuch, Thomas ^e   Laurenson, Ian F ^f   Leitch, Andrew ^g   Loebinger, Michael R ^h   Milburn, Heather J ⁱ   Nightingale, Mark ^j   Ormerod, Peter ^k   Shingadia, Delane ^l   Smith, David ^m   Whitehead, Nuala ⁿ   Wilson, Robert ^h   Floto, R Andres ^a,o  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b PRINCESS OF WALES HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j BRITISH THORACIC SOCIETY   (United Kingdom)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^m SOUTHMEAD HOSPITAL   (United Kingdom)

ⁿ QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^o UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; BEDAQUILINE; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOXYCYCLINE; ETHAMBUTOL; GAMMA INTERFERON; IMIPENEM; ISONIAZID; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; BACTERIAL TRANSMISSION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; GENE SEQUENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG FIBROSIS; LUNG TRANSPLANTATION; LUNG TUBERCULOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM XENOPEI; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROLOGY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; THROAT CULTURE; TIME TO TREATMENT; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; DISEASE MANAGEMENT; HUMAN; ISOLATION AND PURIFICATION; LUNG DISEASE; MEDICAL SOCIETY; MICROBIOLOGY; PULMONOLOGY; UNITED KINGDOM;

ANTI-INFECTIVE AGENTS; DISEASE MANAGEMENT; HUMANS; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PRACTICE GUIDELINES AS TOPIC; PULMONARY MEDICINE; SOCIETIES, MEDICAL; UNITED KINGDOM;

EID: 85032024845     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2017-210927     Document Type: Review

References (336)

1. Griffth DE, Aksamit T, Brown-Elliott BA, et al. An offcial ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
2. NICE. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Secondary Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011 https://www.nice.org.uk/guidance/cg117
3. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000;55:210-8.
4. Matveychuk A, Fuks L, Priess R, et al. Clinical and radiological features of Mycobacterium kansasii and other NTM infections. Respir Med 2012;106:1472-7.
5. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989;321:863-8.
6. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-6.
7. Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013;42:1604-13.
8. Bodle EE, Cunningham JA, Della-Latta P, et al. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008;14:390-6.
9. Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare benefciaries. Am J Respir Crit Care Med 2012;185:881-6.
10. Adjemian J, Olivier KN, Seitz AE, et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012;186:553-8.
11. Pedro HS, Pereira MI, Goloni MR, et al. Nontuberculous mycobacteria isolated in São José do Rio Preto, Brazil between 1996 and 2005. J Bras Pneumol 2008;34:950-5.
12. Davies BS, Roberts CH, Kaul S, et al. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. Scand J Infect Dis 2012;44:815-9.
13. Moore JE, Kruijshaar ME, Ormerod L P, et al. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 2010;10:612.
14. Gerogianni I, Papala M, Kostikas K, et al. Epidemiology and clinical signifcance of mycobacterial respiratory infections in Central Greece. Int J Tuberc Lung Dis 2008;12:807-12.
15. van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64:502-6.
16. Aliyu G, El-Kamary SS, Abimiku A, et al. Prevalence of non-tuberculous mycobacterial infections among tuberculosis suspects in Nigeria. PLoS One 2013;8:e63170.
17. Asiimwe BB, Bagyenzi GB, Ssengooba W, et al. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. BMC Infect Dis 2013;13:88.
18. Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011;17:343-9.
19. Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 2014;11:1-8.
20. Lai CC, Tan CK, Chou CH, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 2010;16:294-6.
21. Jing H, Wang H, Wang Y, et al. Prevalence of nontuberculous mycobacteria infection, China, 2004-2009. Emerg Infect Dis 2012;18:527-8.
22. Shao Y, Chen C, Song H, et al. The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Negl Trop Dis 2015;9:e0003623.
23. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015;36:13-34.
24. Falkinham JO. Environmental sources of nontuberculous mycobacteria. Clin Chest Med 2015;36:35-41.
25. Thomson RM, Nwga QTC C. Queensland Mycobacterial Reference L. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Diseases 2010;16:1576-83.
26. Chou M P, Clements AC, Thomson RM. A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis 2014;14:279.
27. Koh WJ, Chang B, Jeong BH, et al. Increasing Recovery of Nontuberculous Mycobacteria from Respiratory Specimens over a 10-Year Period in a Tertiary Referral Hospital in South Korea. Tuberc Respir Dis 2013;75:199-204.
28. Andréjak C, Thomsen VØ, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010;181:514-21.
29. Marras TK, Mendelson D, Marchand-Austin A, et al. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013;19:1889-91.
30. Shah NM, Davidson JA, Anderson L F, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis 2016;16:195.
31. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fbrosis patients to mycobacterial infection. J Clin Invest 2011;121:3554-63.
32. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007;176:306-13.
33. Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis 2014;18:1370-7.
34. Falkinham JO. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011;17:419-24.
35. Falkinham JO. Current Epidemiologic Trends of the Nontuberculous Mycobacteria (NTM). Curr Environ Health Rep 2016;3:161-7.
36. Feazel LM, Baumgartner LK, Peterson KL, et al. Opportunistic pathogens enriched in showerhead bioflms. Proc Natl Acad Sci U S A 2009;106:16393-9.
37. Thomson R, Tolson C, Carter R, et al. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol 2013;51:3006-11.
38. Catherinot E, Roux AL, Vibet MA, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fbrosis patient subpopulations. J Cyst Fibros 2013;12:74-80.
39. Bryant JM, Grogono DM, Parkhill J, et al. Transmission of M abscessus in patients with cystic fbrosis - Authors' reply. Lancet 2013;382:504.
40. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fbrosis: a retrospective cohort study. Lancet 2013;381:1551-60.
41. Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016;354:751-7.
42. Donohue MJ, Mistry JH, Donohue JM, et al. Increased Frequency of Nontuberculous Mycobacteria Detection at Potable Water Taps within the United States. Environ Sci Technol 2015;49:6127-33.
43. Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fbrosis patients, Israel. Emerg Infect Dis 2008;14:378-84.
44. Bloch KC, Zwerling L, Pletcher MJ, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998;129:698-704.
45. Hojo M, Iikura M, Hirano S, et al. Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy. Respirology 2012;17:185-90.
46. Henry M T, Inamdar L, O'Riordain D, et al. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 2004;23:741-6.
47. Marras TK, Mehta M, Chedore P, et al. Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung 2010;188:289-99.
48. Chan ED, Kaminska AM, Gill W, et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 2007;39:690-6.
49. Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68:256-62.
50. McGrath EE, Bardsley P. An association between Mycobacterium malmoense and coal workers' pneumoconiosis. Lung 2009;187:51-4.
51. Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among patients with cystic fbrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 2014;190:581-6.
52. Leung JM, Olivier KN. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fbrosis. Curr Opin Pulm Med 2013;19:662-9.
53. Griffth DE, Aksamit TR, Timothy R. Bronchiectasis and nontuberculous mycobacterial disease. Clin Chest Med 2012;33:283-95.
54. Mirsaeidi M, Hadid W, Ericsoussi B, et al. Non-tuberculous mycobacterial disease is common in patients with non-cystic fbrosis bronchiectasis. Int J Infect Dis 2013;17:e1000-4.
55. Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005;60:1045-51.
56. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004;169:459-67.
57. Mussaff H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fbrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005;25:324-8.
58. Kunst H, Wickremasinghe M, Wells A, et al. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J 2006;28:352-7.
59. Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med 2013;187:1374-81.
60. Jang MA, Kim S Y, Jeong BH, et al. Association of CFTR gene variants with nontuberculous mycobacterial lung disease in a Korean population with a low prevalence of cystic fbrosis. J Hum Genet 2013;58:298-303.
61. Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med 2013;34:110-23.
62. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992;101:1605-9.
63. Colombo RE, Hill SC, Claypool RJ, et al. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010;137:629-34.
64. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178:1066-74.
65. Leung JM, Fowler C, Smith C, et al. A familial syndrome of pulmonary nontuberculous mycobacteria infections. Am J Respir Crit Care Med 2013;188:1373-6.
66. Kartalija M, Ovrutsky AR, Bryan CL, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013;187:197-205.
67. Szymanski E P, Leung JM, Fowler CJ, et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. Am J Respir Crit Care Med 2015;192:618-28.
68. Thomson RM, Armstrong JG, Looke D F, et al. acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007;131:1166-72.
69. Koh WJ, Lee JH, Kwon YS, et al. Prevalence of gastroesophageal refux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007;131:1825-30.
70. Liao TL, Lin C F, Chen YM, et al. Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area. Sci Rep 2016;6:29443.
71. Liao TL, Lin CH, Shen GH, et al. Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001-2011. Emerg Infect Dis 2015;21:1387-95.
72. Brode SK, Jamieson FB, Ng R, et al. Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest 2014;146:563-72.
73. Gelder CM, Hart KW, Williams OM, et al. Vitamin D receptor gene polymorphisms and susceptibility to Mycobacterium malmoense pulmonary disease. J Infect Dis 2000;181:2099-102.
74. Jeon K, Kim S Y, Jeong BH, et al. Severe vitamin D defciency is associated with non-tuberculous mycobacterial lung disease: a case-control study. Respirology 2013;18:983-8.
75. Okumura M, Iwai K, Ogata H, et al. Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med 2008;47:1465-72.
76. Roux AL, Catherinot E, Soismier N, et al. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fbrosis patients. J Cyst Fibros 2015;14:63-9.
77. Cegielski J P, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004;8:286-98.
78. Lee SJ, Ryu YJ, Lee JH, et al. The impact of low subcutaneous fat in patients with nontuberculous mycobacterial lung disease. Lung 2014;192:395-401.
79. Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015;15:968-80.
80. Lake MA, Ambrose LR, Lipman MC, et al. "Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med 2016;14:54.
81. Sologuren I, Boisson-Dupuis S, Pestano J, et al. Partial recessive IFN-γR1 defciency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet 2011;20:1509-23.
82. Kristensen IA, Veirum JE, Møller BK, et al. Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. J Clin Immunol 2011;31:265-71.
83. Hsu A P, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011;118:2653-5.
84. Sapkota BR, Hijikata M, Matsushita I, et al. Association of SLC11A1 (NRAMP1) polymorphisms with pulmonary Mycobacterium avium complex infection. Hum Immunol 2012;73:529-36.
85. Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med 2015;36:91-9.
86. Browne SK. Anticytokine autoantibody-associated immunodefciency. Annu Rev Immunol 2014;32:635-57.
87. Dirac MA, Horan KL, Doody DR, et al. Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;186:684-91.
88. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009;15:1556-61.
89. Viviani L, Harrison MJ, Zolin A, et al. Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fbrosis (CF). J Cyst Fibros 2016;15:619-23.
90. Girón RM, Máiz L, Barrio I, et al. [Nontuberculous mycobacterial infection in patients with cystic fbrosis: a multicenter prevalence study]. Arch Bronconeumol 2008;44:679-84.
91. Radhakrishnan DK, Yau Y, Corey M, et al. Non-tuberculous mycobacteria in children with cystic fbrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009;44:1100-6.
92. Verregghen M, Heijerman HG, Reijers M, et al. Risk factors for Mycobacterium abscessus infection in cystic fbrosis patients; a case-control study. J Cyst Fibros 2012;11:340-3.
93. Coolen N, Morand P, Martin C, et al. Reduced risk of nontuberculous mycobacteria in cystic fbrosis adults receiving long-term azithromycin. J Cyst Fibros 2015;14:594-9.
94. Catherinot E, Roux AL, Vibet MA, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fbrosis patients. Eur Respir J 2013;41:1101-6.
95. Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fbrosis. Am J Respir Crit Care Med 2013;188:807-12.
96. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996;9:177-215.
97. Klausen J, Giese SB, Fuursted K, et al. Distribution of serotypes, IS901 and a 40 kDa protein in Mycobacterium avium complex strains isolated from man and animals in Denmark APMIS, et immunologica Scandinavica. 1997;105:277-82.
98. Feizabadi MM, Robertson ID, Cousins D V, et al. Genetic characterization of Mycobacterium avium isolates recovered from humans and animals in Australia. Epidemiol Infect 1996;116:41-9.
99. Olivier KN, Weber DJ, Wallace RJ, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fbrosis. Am J Respir Crit Care Med 2003;167:828-34.
100. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fbrosis. Emerg Infect Dis 2003;9:1587-91.
101. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fbrosis center. Am J Respir Crit Care Med 2012;185:231-2.
102. Davidson RM, Hasan NA, Reynolds PR, et al. Genome sequencing of Mycobacterium abscessus isolates from patients in the united states and comparisons to globally diverse clinical strains. J Clin Microbiol 2014;52:3573-82.
103. Harris KA, Underwood A, Kenna DT, et al. Whole-genome sequencing and epidemiological analysis do not provide evidence for cross-transmission of mycobacterium abscessus in a cohort of pediatric cystic fbrosis patients. Clin Infect Dis 2015;60:1007-16.
104. Foundation C F. Infection Prevention and Control Care Guidelines. Secondary Infection Prevention and Control Care Guidelines. 2014. https://www. cff. org/For-Caregivers/Clinical-Care-Guidelines/Infection-Prevention-and-Control-Care-Guidelines/
105. Group TUCFTMaICW. Mycobacterium abscessus Suggestions for infection prevention and control (Interim guidance - October 2013): Cystic Fibrosis Trust. 2013.
106. Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest 1991;99:667-9.
107. Lee MR, Yang C Y, Shu CC, et al. Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination. Clin Microbiol Infect 2015;21:250.e1-250.e7.
108. Koh WJ, Chang B, Ko Y, et al. Clinical signifcance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens. Diagn Microbiol Infect Dis 2013;75:225-6.
109. Martiniano SL, Sontag MK, Daley CL, et al. Clinical signifcance of a first positive nontuberculous mycobacteria culture in cystic fbrosis. Ann Am Thorac Soc 2014;11:36-44.
110. Tukey MH, Wiener RS. Population-based estimates of transbronchial lung biopsy utilization and complications. Respir Med 2012;106:1559-65.
111. Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997;155:2041-6.
112. Sugihara E, Hirota N, Niizeki T, et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection. J Infect Chemother 2003;9:328-32.
113. van Ingen J. Diagnosis of nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013;34:103-9.
114. Delogu G, Hermann JL. Mycobacterium species. ESCMID-SFM Manual of Microbiology 2010.
115. Traore I, Slosárek M. Survival of mycobacteria in sputum at different temperatures. Czech Med 1981;4:203-8.
116. Tessema B, Beer J, Emmrich F, et al. Rate of recovery of Mycobacterium tuberculosis from frozen acid-fast-bacillus smear-positive sputum samples subjected to long-term storage in Northwest Ethiopia. J Clin Microbiol 2011;49:2557-61.
117. von Reyn C F, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purifed protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001;5:1122-8.
118. Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969;99:Suppl:1-132.
119. Stavri H, Ulea I, Radu DL, et al. Serodiagnosis of environmental mycobacterial infections. J Microbiol Methods 2011;86:283-90.
120. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004;38:1428-39.
121. Kitada S, Kobayashi K, Ichiyama S, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med 2008;177:793-7.
122. Kobayashi K. Serodiagnosis of Mycobacterium avium complex disease in humans: translational research from basic mycobacteriology to clinical medicine. Jpn J Infect Dis 2014;67:329-32.
123. Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, et al. Measurement of immunoglobulin G against Mycobacterial antigen A60 in patients with cystic fbrosis and lung infection due to Mycobacterium abscessus. Clin Infect Dis 2005;40:58-66.
124. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:570-81.
125. Ulukanligil M, Aslan G, Tasçi S. A comparative study on the different staining methods and number of specimens for the detection of acid fast bacilli. Mem Inst Oswaldo Cruz 2000;95:855-8.
126. Wright PW, Wallace RJ, Wright NW, et al. Sensitivity of fuorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria. J Clin Microbiol 1998;36:1046-9.
127. Murray SJ, Barrett A, Magee JG, et al. Optimisation of acid fast smears for the direct detection of mycobacteria in clinical samples. J Clin Pathol 2003;56:613-5.
128. Kim S, Park EM, Kwon OJ, et al. Direct application of the PCR restriction analysis method for identifying NTM species in AFB smear-positive respiratory specimens. Int J Tuberc Lung Dis 2008;12:1344-6.
129. Franco-Alvarez de Luna F, Ruiz P, Gutiérrez J, et al. Evaluation of the GenoType Mycobacteria Direct assay for detection of Mycobacterium tuberculosis complex and four atypical mycobacterial species in clinical samples. J Clin Microbiol 2006;44:3025-7.
130. Seagar AL, Prendergast C, Emmanuel FX, et al. Evaluation of the GenoType Mycobacteria Direct assay for the simultaneous detection of the Mycobacterium tuberculosis complex and four atypical mycobacterial species in smear-positive respiratory specimens. J Med Microbiol 2008;57:605-11.
131. Perry MD, White PL, Ruddy M. Potential for use of the Seegene Anyplex MTB/ NTM real-time detection assay in a regional reference laboratory. J Clin Microbiol 2014;52:1708-10.
132. Buijtels PC, Petit PL. Comparison of NaOH-N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens. J Microbiol Methods 2005;62:83-8.
133. Bange FC, Böttger EC. Improved decontamination method for recovering mycobacteria from patients with cystic fbrosis. Eur J Clin Microbiol Infect Dis 2002;21:546-8.
134. Brown-Elliott BA, Griffth DE, Wallace RJ. Diagnosis of nontuberculous mycobacterial infections. Clin Lab Med 2002;22:911-25.
135. Whittier S, Olivier K, Gilligan P, et al. Profciency testing of clinical microbiology laboratories using modifed decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fbrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. J Clin Microbiol 1997;35:2706-8.
136. van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med 2015;36:43-54.
137. Esther CR, Hoberman S, Fine J, et al. Detection of rapidly growing mycobacteria in routine cultures of samples from patients with cystic fbrosis. J Clin Microbiol 2011;49:1421-5.
138. Eltringham I, Pickering J, Gough H, et al. Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis. J Clin Microbiol 2016;54:2047-50.
139. Preece CL, Perry A, Gray B, et al. A novel culture medium for isolation of rapidly-growing mycobacteria from the sputum of patients with cystic fbrosis. J Cyst Fibros 2016;15:186-91.
140. Hanna BA, Ebrahimzadeh A, Elliott LB, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol 1999;37:748-52.
141. Wagner D, Vos M, Buiting AG, et al. "Mycobacterium tilburgii" infections. Emerg Infect Dis 2006;12:532-4.
142. Standards Unit MS. UK Standards for Microbiology Investigations. Investigation of specifments for Mycobacteriam species B40: PHE 2014.
143. Brown-Elliott BA, Wallace RJ. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716-46.
144. Koh WJ, Jeon K, Lee N Y, et al. Clinical signifcance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-10.
145. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012;186:917-25.
146. Kim H Y, Kim BJ, Kook Y, et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010;54:347-53.
147. Saleeb PG, Drake SK, Murray PR, et al. Identifcation of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of fight mass spectrometry. J Clin Microbiol 2011;49:1790-4.
148. Lotz A, Ferroni A, Beretti JL, et al. Rapid identifcation of mycobacterial whole cells in solid and liquid culture media by matrix-assisted laser desorption ionization-time of fight mass spectrometry. J Clin Microbiol 2010;48:4481-6.
149. Pignone M, Greth KM, Cooper J, et al. Identifcation of mycobacteria by matrix-assisted laser desorption ionization-time-of-fight mass spectrometry. J Clin Microbiol 2006;44:1963-70.
150. El Khéchine A, Couderc C, Flaudrops C, et al. Matrix-assisted laser desorption/ ionization time-of-fight mass spectrometry identifcation of mycobacteria in routine clinical practice. PLoS One 2011;6:e24720.
151. Bille E, Dauphin B, Leto J, et al. MALDI-TOF MS Andromas strategy for the routine identifcation of bacteria, mycobacteria, yeasts, Aspergillus spp. and positive blood cultures. Clin Microbiol Infect 2012;18:1117-25.
152. Fangous MS, Mougari F, Gouriou S, et al. Classifcation algorithm for subspecies identifcation within the Mycobacterium abscessus species, based on matrix-assisted laser desorption ionization-time of fight mass spectrometry. J Clin Microbiol 2014;52:3362-9.
153. Rodríguez-Sánchez B, Ruiz-Serrano MJ, Marín M, et al. Evaluation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identifcation of Nontuberculous Mycobacteria from Clinical Isolates. J Clin Microbiol 2015;53:2737-40.
154. Suffys PN, da Silva Rocha A, de Oliveira M, et al. Rapid identifcation of Mycobacteria to the species level using INNO-LiPA Mycobacteria, a reverse hybridization assay. J Clin Microbiol 2001;39:4477-82.
155. Lebrun L, Gönüllü N, Boutros N, et al. Use of INNO-LIPA assay for rapid identifcation of mycobacteria. Diagn Microbiol Infect Dis 2003;46:151-3.
156. Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identifcation. J Clin Microbiol 2003;41:4418-20.
157. Lebrun L, Weill FX, Lafendi L, et al. Use of the INNO-LiPA-MYCOBACTERIA assay (version 2) for identifcation of Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum complex isolates. J Clin Microbiol 2005;43:2567-74.
158. Telenti A, Marchesi F, Balz M, et al. Rapid identifcation of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993;31:175-8.
159. Devallois A, Goh KS, Rastogi N. Rapid identifcation of mycobacteria to species level by PCR-restriction fragment length polymorphism analysis of the hsp65 gene and proposition of an algorithm to differentiate 34 mycobacterial species. J Clin Microbiol 1997;35:2969-73.
160. Leao SC, Tortoli E, Euzéby J P, et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassifed as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011;61:2311-3.
161. Ringuet H, Akoua-Koff C, Honore S, et al. hsp65 sequencing for identifcation of rapidly growing mycobacteria. J Clin Microbiol 1999;37:852-7.
162. Macheras E, Roux AL, Ripoll F, et al. Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group. J Clin Microbiol 2009;47:2596-600.
163. Kim K, Hong SH, Kim BJ, et al. Separation of Mycobacterium abscessus into subspecies or genotype level by direct application of peptide nucleic acid multi-probe- real-time PCR method into sputa samples. BMC Infect Dis 2015;15:325.
164. Macheras E, Roux AL, Bastian S, et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol 2011;49:491-9.
165. Macheras E, Konjek J, Roux AL, et al. Multilocus sequence typing scheme for the Mycobacterium abscessus complex. Res Microbiol 2014;165:82-90.
166. Hoffner SE, Svenson SB, Källenius G. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. Eur J Clin Microbiol 1987;6:530-5.
167. Banks J, Jenkins PA. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987;42:838-42.
168. Heifets LB. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis 1982;125:43-8.
169. Woods GL, Brown-Elliott BA, Conville PS, et al. M24 Susceptibility Testing of Mycobacteria Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. 2nd Edition, 2011.
170. van Ingen J, Egelund E F, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186:559-65.
171. van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012;15:149-61.
172. Chaisson RE, Benson CA, Dube M P, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994;121:905-11.
173. Wallace RJ, Brown BA, Griffth DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996;153:1766-72.
174. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-72.
175. Griffth DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;174:928-34.
176. Morimoto K, Namkoong H, Hasegawa N, et al. Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. Ann Am Thorac Soc 2016;13:1904-11.
177. Brown-Elliott BA, Iakhiaeva E, Griffth DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and fnding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 2013;51:3389-94.
178. Sison J P, Yao Y, Kemper CA, et al. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J Infect Dis 1996;173:677-83.
179. Ahn CH, Wallace RJ, Steele LC, et al. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 1987;135:10-16.
180. Wallace RJ, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994;18:736-43.
181. van Ingen J, Totten SE, Heifets LB, et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012;39:173-6.
182. Wallace RJ, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152:500-14.
183. Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52:565-71.
184. Prajapati S, Upadhyay K, Mukherjee A, et al. High prevalence of primary drug resistance in children with intrathoracic tuberculosis in India. Paediatr Int Child Health 2016;36:0000000041.
185. Griffth DE, Adjemian J, Brown-Elliott BA, et al. Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med 2015;192:754-60.
186. Ikedo Y. The signifcance of bronchoscopy for the diagnosis of Mycobacterium avium complex (MAC) pulmonary disease. Kurume Med J 2001;48:15-19.
187. Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999;115:1033-40.
188. Ahn CH, McLarty JW, Ahn SS, et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 1982;125:388-91.
189. Lam PK, Griffth DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-9.
190. Hollings N P, Wells AU, Wilson R, et al. Comparative appearances of non-tuberculous mycobacteria species: a CT study. Eur Radiol 2002;12:2211-7.
191. Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology 1993;187:777-82.
192. McEvoy S, Lavelle L, Kilcoyne A, et al. High-resolution CT of nontuberculous mycobacterium infection in adult CF patients: diagnostic accuracy. Eur Radiol 2012;22:2736-42.
193. Obayashi Y, Fujita J, Suemitsu I, et al. Successive follow-up of chest computed tomography in patients with Mycobacterium avium-intracellulare complex. Respir Med 1999;93:11-15.
194. Maycher B, O'Connor R, Long R. Computed tomographic abnormalities in Mycobacterium avium complex lung disease include the mosaic pattern of reduced lung attenuation. Can Assoc Radiol J 2000;51:93-102.
195. Ferrara I, Cappabianca S, Brunese L, et al. HRCT in detection of pulmonary infections from nontuberculous mycobacteria: personal experience. Radiol Med 2009;114:376-89.
196. Lynch DA, Simone PM, Fox MA, et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr 1995;19:353-60.
197. Kitada S, Uenami T, Yoshimura K, et al. Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Int J Tuberc Lung Dis 2012;16:660-4.
198. Zoumot Z, Boutou AK, Gill SS, et al. Mycobacterium avium complex infection in non-cystic fbrosis bronchiectasis. Respirology 2014;19:714-22.
199. Primack SL, Logan PM, Hartman TE, et al. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT fndings. Radiology 1995;194:413-7.
200. Ushiki A, Yamazaki Y, Koyama S, et al. Bronchoscopic microsampling for bacterial colony counting in relevant lesions in patients with pulmonary Mycobacterium avium complex infection. Intern Med 2011;50:1287-92.
201. Hayashi M, Takayanagi N, Kanauchi T, et al. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;185:575-83.
202. Shu CC, Lee CH, Hsu CL, et al. Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns. Lung 2011;189:467-74.
203. Kuroishi S, Nakamura Y, Hayakawa H, et al. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography fndings. Eur Respir J 2008;32:147-52.
204. Lee G, Lee KS, Moon JW, et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. Ann Am Thorac Soc 2013;10:299-306.
205. Takeda K, Imamura Y, Takazono T, et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol 2016;54:120-7.
206. Jeong BH, Kim S Y, Jeon K, et al. Serodiagnosis of Mycobacterium avium complex and Mycobacterium abscessus complex pulmonary disease by use of IgA antibodies to glycopeptidolipid core antigen. J Clin Microbiol 2013;51:2747-9.
207. Kitada S, Levin A, Hiserote M, et al. Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J 2013;42:454-60.
208. Shu CC, Ato M, Wang JT, et al. Sero-diagnosis of Mycobacterium avium complex lung disease using serum immunoglobulin A antibody against glycopeptidolipid antigen in Taiwan. PLoS One 2013;8:e80473.
209. Qvist T, Pressler T, Taylor-Robinson D, et al. Serodiagnosis of Mycobacterium abscessus complex infection in cystic fbrosis. Eur Respir J 2015;46:707-16.
210. Huebner RE, Schein M F, Cauthen GM, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis 1992;145:1160-6.
211. Ra SW, Lyu J, Choi CM, et al. Distinguishing tuberculosis from Mycobacterium avium complex disease using an interferon-gamma release assay. Int J Tuberc Lung Dis 2011;15:635-40.
212. Demura Y, Tsuchida T, Uesaka D, et al. Usefulness of 18F-fuorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 2009;36:632-9.
213. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-72.
214. Jenkins PA, Campbell IA, Banks J, et al. Clarithromycin vs ciprofoxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008;63:627-34.
215. Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fbrosis in france. J Clin Microbiol 2009;47:4124-8.
216. Harada T, Akiyama Y, Kurashima A, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012;50:3556-61.
217. Lyu J, Jang HJ, Song JW, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011;105:781-7.
218. Boyle D P, Zembower TR, Reddy S, et al. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Am J Respir Crit Care Med 2015;191:1310-7.
219. Koh WJ, Jeong BH, Jeon K, et al. Clinical signifcance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. Chest 2012;142:1482-8.
220. Kim S Y, Lee ST, Jeong BH, et al. Clinical signifcance of mycobacterial genotyping in Mycobacterium avium lung disease in Korea. Int J Tuberc Lung Dis 2012;16:1393-9.
221. Kikuchi T, Kobashi Y, Hirano T, et al. Mycobacterium avium genotype is associated with the therapeutic response to lung infection. Clin Microbiol Infect 2014;20:256-62.
222. Shin SJ, Choi GE, Cho SN, et al. Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 2013;57:32-9.
223. Ito Y, Hirai T, Maekawa K, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 2012;16:408-14.
224. Kitada S, Maekura R, Toyoshima N, et al. Use of glycopeptidolipid core antigen for serodiagnosis of mycobacterium avium complex pulmonary disease in immunocompetent patients. Clin Diagn Lab Immunol 2005;12:44-51.
225. Kitada S, Nishiuchi Y, Hiraga T, et al. Serological test and chest computed tomography fndings in patients with Mycobacterium avium complex lung disease. Eur Respir J 2007;29:1217-23.
226. Russell CD, Claxton P, Doig C, et al. Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax 2014;69:593-5.
227. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007;101:130-8.
228. Tsukamura M, Ichiyama S, Miyachi T. Superiority of enviomycin or streptomycin over ethambutol in initial treatment of lung disease caused by Mycobacterium avium complex. Chest 1989;95:1056-8.
229. Ahn CH, Ahn SS, Anderson RA, et al. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986;134:438-41.
230. Dutt AK, Stead WW. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med 1979;67:449-53.
231. Fujita M, Kajiki A, Tao Y, et al. The clinical effcacy and safety of a fuoroquinolone-containing regimen for pulmonary MAC disease. J Infect Chemother 2012;18:146-51.
232. Miwa S, Shirai M, Toyoshima M, et al. Effcacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc 2014;11:23-9.
233. Sim YS, Park H Y, Jeon K, et al. Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Med J 2010;51:888-94.
234. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007;74:394-400.
235. Griffth DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001;32:1547-53.
236. Griffth DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-92.
237. Wallace RJ, Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/ bronchiectatic mycobacterium avium complex lung disease. Chest 2014;146:276-82.
238. Jeong BH, Jeon K, Park H Y, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015;191:96-103.
239. Koh WJ, Jeong BH, Jeon K, et al. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother 2015;59:4994-6.
240. Kobashi Y, Abe M, Mouri K, et al. Relationship between clinical effcacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012;18:436-43.
241. Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009;136:1569-75.
242. Kobashi Y, Matsushima T. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease. Intern Med 2003;42:670-5.
243. Griffth DE, Brown BA, Girard WM, et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodefciency virus. Clin Infect Dis 1996;23:983-9.
244. Wallace RJ, Brown BA, Griffth DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-21.
245. Griffth DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-8.
246. Wallace RJ, Brown BA, Griffth DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-41.
247. Brown BA, Griffth DE, Girard W, et al. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis 1997;24:958-64.
248. Griffth DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodefciency virus-negative patients. J Infect Dis 1998;178:121-6.
249. Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune defciency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis 1998;2:462-70.
250. Davidson PT, Khanijo V, Goble M, et al. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981;3:1052-9.
251. Hunter AM, Campbell IA, Jenkins PA, et al. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax 1981;36:326-9.
252. Jo KW, Kim S, Lee J Y, et al. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear effcacy. J Infect Chemother 2014;20:602-6.
253. Koh WJ, Hong G, Kim S Y, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifoxacin-containing regimen. Antimicrob Agents Chemother 2013;57:2281-5.
254. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124:1482-6.
255. Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J 2015;45:1177-9.
256. Philley J V, Wallace RJ, Benwill JL, et al. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest 2015;148:499-506.
257. Jarand J, Davis J P, Cowie RL, et al. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/ or Rifampin. Chest 2016;149:1285-93.
258. Davis KK, Kao PN, Jacobs SS, et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7:2.
259. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014;11:30-5.
260. Olivier KN, Griffth DE, Eagle G, et al. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med 2017;195:814-823.
261. van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012;56:6324-7.
262. Jenkins PA, Banks J, Campbell IA, et al. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994;49:442-5.
263. Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983;128:1048-50.
264. Sauret J, Hernández-Flix S, Castro E, et al. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tuber Lung Dis 1995;76:104-8.
265. Griffth DE, Brown-Elliott BA, Wallace RJ. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003;37:1178-82.
266. Ahn CH, Lowell JR, Ahn SS, et al. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: effcacies of some individual drugs. Rev Infect Dis 1981;3:1028-34.
267. Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981;3:1035-9.
268. Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983;38:271-4.
269. Evans AJ, Crisp AJ, Hubbard RB, et al. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax 1996;51:1243-7.
270. Santin M, Dorca J, Alcaide F, et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 2009;33:148-52.
271. Park HK, Koh WJ, Shim TS, et al. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. Yonsei Med J 2010;51:552-6.
272. Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006;129:771-6.
273. Banks J, Jenkins PA, Smith A P. Pulmonary infection with Mycobacterium malmoense-a review of treatment and response. Tubercle 1985;66:197-203.
274. Murray M P, Laurenson I F, Hill AT. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin Infect Dis 2008;47:222-4.
275. Hoefsloot W, van Ingen J, de Lange WC, et al. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009;34:926-31.
276. Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis 2009;13:1210-8.
277. Costrini AM, Mahler DA, Gross WM, et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981;123:104-9.
278. Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax 1983;38:373-7.
279. Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax 1984;39:376-82.
280. Johnston ID. Mycobacterium xenopi infection and aspergilloma. Tubercle 1988;69:139-43.
281. Contreras MA, Cheung OT, Sanders DE, et al. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis 1988;137:149-52.
282. Al Jarad N, Demertzis P, Jones DJ, et al. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax 1996;51:137-9.
283. van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008;14:385-9.
284. Andréjak C, Lescure FX, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009;64:291-6.
285. Jeon K, Kwon OJ, Lee N Y, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.
286. Maurer F P, Castelberg C, Quiblier C, et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 2014;69:1559-63.
287. Lyu J, Kim BJ, Kim BJ, et al. A shorter treatment duration may be suffcient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med 2014;108:1706-12.
288. Wallace RJ, Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014;69:1945-53.
289. Shen GH, Wu BD, Hu S T, et al. High effcacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010;35:400-4.
290. Dubée V, Bernut A, Cortes M, et al. β-Lactamase inhibition by avibactam in Mycobacterium abscessus. J Antimicrob Chemother 2015;70:1051-8.
291. Milanés-Virelles MT, García-García I, Santos-Herrera Y, et al. Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. BMC Infect Dis 2008;8:17.
292. Maekawa K, Ito Y, Oga T, et al. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tuberc Lung Dis 2013;17:829-35.
293. Koh WJ, Jeong BH, Jeon K, et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;186:797-802.
294. Magis-Escurra C, Alffenaar JW, Hoefnagels I, et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents 2013;42:256-61.
295. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538-44.
296. Prezant TR, Agapian J V, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993;4:289-94.
297. Griffth DE, Brown-Elliott BA, Shepherd S, et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005;172:250-3.
298. Varughese A, Brater DC, Benet LZ, et al. Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis 1986;134:34-8.
299. Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557-70.
300. Ray WA, Murray K T, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
301. Marras TK, Prevots DR, Jamieson FB, et al. Opinions differ by expertise in Mycobacterium avium complex disease. Ann Am Thorac Soc 2014;11:17-22.
302. Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc 2014;11:9-16.
303. Yu JA, Pomerantz M, Bishop A, et al. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardiothorac Surg 2011;40:671-5.
304. Corpe R F. Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev Infect Dis 1981;3:1064-7.
305. Koh WJ, Kim YH, Kwon OJ, et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci 2008;23:397-401.
306. Law SW. Surgical treatment of atypical mycobacterial disease; a survey of experience in veterans administration hospitals. Dis Chest 1965;47:296-303.
307. Mitchell JD, Bishop A, Cafaro A, et al. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008;85:1887-93.
308. Moran J F, Alexander LG, Staub EW, et al. Long-term results of pulmonary resection for atypical mycobacterial disease. Ann Thorac Surg 1983;35:597-604.
309. Muangsombut J, Hankins JR, Miller JE, et al. Surgical treatment of pulmonary infections caused by atypical mycobacteria. Am Surg 1975;41:37-40.
310. Nelson KG, Griffth DE, Brown BA, et al. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998;66:325-9.
311. Ono N, Satoh K, Yokomise H, et al. Surgical management of Mycobacterium avium complex disease. Thorac Cardiovasc Surg 1997;45:311-3.
312. Parrot RG, Grosset JH. Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle 1988;69:47-55.
313. Shiraishi Y, Fukushima K, Komatsu H, et al. Early pulmonary resection for localized Mycobacterium avium complex disease. Ann Thorac Surg 1998;66:183-6.
314. Shiraishi Y, Nakajima Y, Takasuna K, et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg 2002;21:314-8.
315. Shiraishi Y, Katsuragi N, Kita H, et al. Different morbidity after pneumonectomy: multidrug-resistant tuberculosis versus non-tuberculous mycobacterial infection. Interact Cardiovasc Thorac Surg 2010;11:429-32.
316. Tsunezuka Y, Sato H, Hiranuma C. Surgical outcome of mycobacterium other than mycobacterium tuberculosis pulmonary disease. Thorac Cardiovasc Surg 2000;48:290-3.
317. van Ingen J, Verhagen A F, Dekhuijzen PN, et al. Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis 2010;14:99-105.
318. Watanabe M, Hasegawa N, Ishizaka A, et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann Thorac Surg 2006;81:2026-30.
319. Zvetina JR, Neville WE, Maben HC, et al. Surgical treatment of pulmonary disease due to Mycobacterium kansasii. Ann Thorac Surg 1971;11:551-6.
320. Kang HK, Park H Y, Kim D, et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis 2015;15:76.
321. Shiraishi Y, Katsuragi N, Kita H, et al. Adjuvant surgical treatment of nontuberculous mycobacterial lung disease. Ann Thorac Surg 2013;96:287-91.
322. Wang GS, Wang Z, Yang L, et al. Thoracoscopic management for bronchiectasis with non-tuberculous mycobacterial infection. Chin Med J 2008;121:2539-43.
323. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010;65(Suppl 3):iii1-27.
324. Colice GL, Shafazand S, Griffn J P, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007(3 Suppl):161S-77S.
325. Char A, Hopkinson NS, Hansell DM, et al. Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study. BMC Pulm Med 2014;14:124.
326. Dorman S, Subramanian A. AST Infectious Diseases Community of Practice. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S63-9.
327. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34:1-15.
328. Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012;14:452-60.
329. Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011;30:790-8.
330. Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fbrosis: implications for lung transplantation. Thorax 2006;61:507-13.
331. Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006;25:1447-55.
332. Robinson PD, Harris KA, Aurora P, et al. Paediatric lung transplant outcomes vary with Mycobacterium abscessus complex species. Eur Respir J 2013;41:1230-2.
333. Gilljam M, Scherstén H, Silverborn M, et al. Lung transplantation in patients with cystic fbrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010;9:272-6.
334. Qvist T, Katzenstein TL, Lillebaek T, et al. First report of lung transplantation in a patient with active pulmonary Mycobacterium simiae infection. Transplant Proc 2013;45:803-5.
335. Lobo LJ, Chang LC, Esther CR, et al. Lung transplant outcomes in cystic fbrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013;27:523-9.
336. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fbrosis. Thorax 2016;71(Suppl 1):i1-22.